Charles Schwab Investment Management Inc. Has $383.09 Million Position in Becton, Dickinson and Company (NYSE:BDX)

Charles Schwab Investment Management Inc. increased its position in Becton, Dickinson and Company (NYSE:BDX) by 2.1% during the fourth quarter, Holdings Channel reports. The firm owned 1,571,143 shares of the medical instruments supplier’s stock after buying an additional 31,987 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Becton, Dickinson and Company were worth $383,092,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of BDX. Vanguard Group Inc. boosted its position in Becton, Dickinson and Company by 2.0% during the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock worth $6,703,041,000 after purchasing an additional 516,427 shares during the period. Morgan Stanley raised its holdings in Becton, Dickinson and Company by 4.5% in the 3rd quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock valued at $2,637,062,000 after acquiring an additional 435,168 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of Becton, Dickinson and Company by 11.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock worth $1,342,503,000 after acquiring an additional 512,566 shares during the period. Ameriprise Financial Inc. grew its position in shares of Becton, Dickinson and Company by 9.2% in the third quarter. Ameriprise Financial Inc. now owns 3,630,351 shares of the medical instruments supplier’s stock valued at $938,593,000 after purchasing an additional 304,629 shares during the last quarter. Finally, Clearbridge Investments LLC increased its stake in shares of Becton, Dickinson and Company by 2.9% during the third quarter. Clearbridge Investments LLC now owns 3,135,238 shares of the medical instruments supplier’s stock worth $810,553,000 after purchasing an additional 89,714 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX traded down $3.09 during midday trading on Wednesday, reaching $234.06. 514,847 shares of the company were exchanged, compared to its average volume of 1,398,561. The stock’s 50-day moving average price is $238.27 and its 200-day moving average price is $239.97. The stock has a market cap of $67.64 billion, a P/E ratio of 52.23, a PEG ratio of 1.92 and a beta of 0.45. The company has a quick ratio of 0.97, a current ratio of 1.41 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a one year low of $229.40 and a one year high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business had revenue of $5.05 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same quarter in the prior year, the firm earned $2.86 EPS. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be given a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 1.62%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Analyst Ratings Changes

Separately, Barclays raised their price objective on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Moderate Buy” and a consensus price target of $281.40.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.